Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
PLoS One
2014 Jan 01;911:e112835. doi: 10.1371/journal.pone.0112835.
Show Gene links
Show Anatomy links
Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers.
Sleddering MA
,
Markvoort AJ
,
Dharuri HK
,
Jeyakar S
,
Snel M
,
Juhasz P
,
Lynch M
,
Hines W
,
Li X
,
Jazet IM
,
Adourian A
,
Hilbers PA
,
Smit JW
,
Van Dijk KW
.
???displayArticle.abstract???
UNLABELLED: Very low calorie diets (VLCD) with and without exercise programs lead to major metabolic improvements in obese type 2 diabetes patients. The mechanisms underlying these improvements have so far not been elucidated fully. To further investigate the mechanisms of a VLCD with or without exercise and to uncover possible biomarkers associated with these interventions, blood samples were collected from 27 obese type 2 diabetes patients before and after a 16-week VLCD (Modifast ∼ 450 kcal/day). Thirteen of these patients followed an exercise program in addition to the VCLD. Plasma was obtained from 27 lean and 27 obese controls as well. Proteomic analysis was performed using mass spectrometry (MS) and targeted multiple reaction monitoring (MRM) and a large scale isobaric tags for relative and absolute quantitation (iTRAQ) approach. After the 16-week VLCD, there was a significant decrease in body weight and HbA1c in all patients, without differences between the two intervention groups. Targeted MRM analysis revealed differences in several proteins, which could be divided in diabetes-associated (fibrinogen, transthyretin), obesity-associated (complement C3), and diet-associated markers (apolipoproteins, especially apolipoprotein A-IV). To further investigate the effects of exercise, large scale iTRAQ analysis was performed. However, no proteins were found showing an exercise effect. Thus, in this study, specific proteins were found to be differentially expressed in type 2 diabetes patients versus controls and before and after a VLCD. These proteins are potential disease state and intervention specific biomarkers.
TRIAL REGISTRATION: Controlled-Trials.com ISRCTN76920690.
???displayArticle.pubmedLink???
25415563
???displayArticle.link???PLoS One
Afolabi,
The effect of total starvation and very low energy diet in lean men on kinetics of whole body protein and five hepatic secretory proteins.
2007, Pubmed
Afolabi,
The effect of total starvation and very low energy diet in lean men on kinetics of whole body protein and five hepatic secretory proteins.
2007,
Pubmed
Barazzoni,
Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes.
2003,
Pubmed
Becker,
Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
2003,
Pubmed
Bertile,
A proteomic approach to identify differentially expressed plasma proteins between the fed and prolonged fasted states.
2009,
Pubmed
Caballero,
Effects of physical exercise on some parameters of bone metabolism in postmenopausal women.
1996,
Pubmed
Caballero,
Changes in sex hormone binding globulin, high density lipoprotein cholesterol and plasma lipids in male cyclists during training and competition.
1992,
Pubmed
Centers for Disease Control and Prevention (CDC),
Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002.
2004,
Pubmed
Ceriello,
Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with Type II diabetes mellitus. Relation with beta-fibrinogen genotype.
1998,
Pubmed
Choe,
8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.
2007,
Pubmed
Culnan,
Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass.
2009,
Pubmed
Danaei,
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.
2011,
Pubmed
Dandona,
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
2002,
Pubmed
Ding,
Sex hormone-binding globulin and risk of type 2 diabetes in women and men.
2009,
Pubmed
Donath,
Type 2 diabetes as an inflammatory disease.
2011,
Pubmed
Ehnholm,
Genetic polymorphism of apolipoprotein A-IV in five different regions of Europe. Relations to plasma lipoproteins and to history of myocardial infarction: the EARS study. European Atherosclerosis Research Study.
1994,
Pubmed
Engström,
Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.
2005,
Pubmed
Ernst,
Does weight loss reduce plasma fibrinogen?
1993,
Pubmed
Finucane,
National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants.
2011,
Pubmed
Fujimoto,
Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation.
1992,
Pubmed
García-Ramírez,
Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy.
2007,
Pubmed
Green,
Human apolipoprotein A-IV. Intestinal origin and distribution in plasma.
1980,
Pubmed
Hammer,
Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function.
2008,
Pubmed
Herder,
Biomarkers for the prediction of type 2 diabetes and cardiovascular disease.
2011,
Pubmed
Hernández-Mijares,
Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors.
2007,
Pubmed
Hess,
A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.
2012,
Pubmed
Hoffer,
Metabolic effects of carbohydrate in low-calorie diets.
1984,
Pubmed
Hothorn,
Simultaneous inference in general parametric models.
2008,
Pubmed
Jacobsson,
Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets.
1989,
Pubmed
Jae,
Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus.
2008,
Pubmed
Jazet,
Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes.
2007,
Pubmed
Juhasz,
Semi-targeted plasma proteomics discovery workflow utilizing two-stage protein depletion and off-line LC-MALDI MS/MS.
2011,
Pubmed
Kannel,
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
1990,
Pubmed
Karelis,
Metabolically healthy but obese individuals.
2008,
Pubmed
Kelleher,
Effects of carbohydrate-containing and carbohydrate-restricted hypocaloric and eucaloric diets on serum concentrations of retinol-binding protein, thyroxine-binding prealbumin and transferrin.
1983,
Pubmed
Kim,
Proteome analysis of serum from type 2 diabetics with nephropathy.
2007,
Pubmed
Kramer,
Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis.
2013,
Pubmed
Kriegel,
Identification of diabetes- and obesity-associated proteomic changes in human spermatozoa by difference gel electrophoresis.
2009,
Pubmed
Kronenberg,
Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease.
2000,
Pubmed
Lyons,
Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers.
2012,
Pubmed
Maris,
Type 2 diabetes: Gaining insight into the disease process using proteomics.
2008,
Pubmed
Matthaei,
Pathophysiology and pharmacological treatment of insulin resistance.
2000,
Pubmed
Missov,
Plasma fibrinogen in NIDDM: the Rotterdam study.
1996,
Pubmed
Mokdad,
The continuing epidemics of obesity and diabetes in the United States.
2001,
Pubmed
Onat,
Complement C3 and cleavage products in cardiometabolic risk.
2011,
Pubmed
Pasquali,
Protein metabolism in obese patients during very low-calorie mixed diets containing different amounts of proteins and carbohydrates.
1987,
Pubmed
Quilliot,
Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis.
2001,
Pubmed
Ramalho,
Morbid obesity and inflammation: a prospective study after adjustable gastric banding surgery.
2009,
Pubmed
Rao,
Proteomic identification of salivary biomarkers of type-2 diabetes.
2009,
Pubmed
Riaz,
Proteomic identification of human serum biomarkers in diabetes mellitus type 2.
2010,
Pubmed
Riaz,
Proteomic identification of human urinary biomarkers in diabetes mellitus type 2.
2010,
Pubmed
Ritz,
Gastric bypass is not associated with protein malnutrition in morbidly obese patients.
2009,
Pubmed
Scalfi,
Protein balance during very-low-calorie diets for the treatment of severe obesity.
1987,
Pubmed
Shen,
Hypothalamic apolipoprotein A-IV is regulated by leptin.
2007,
Pubmed
Snel,
Quality of life in type 2 diabetes mellitus after a very low calorie diet and exercise.
2012,
Pubmed
Snel,
Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients.
2012,
Pubmed
Snel,
Effects of adding exercise to a 16-week very low-calorie diet in obese, insulin-dependent type 2 diabetes mellitus patients.
2012,
Pubmed
Snel,
Immediate and long-term effects of addition of exercise to a 16-week very low calorie diet on low-grade inflammation in obese, insulin-dependent type 2 diabetic patients.
2011,
Pubmed
Sun,
Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations.
2000,
Pubmed
Takahashi,
Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway.
2008,
Pubmed
Tso,
Apolipoprotein A-IV, food intake, and obesity.
2004,
Pubmed
Tymchuk,
Changes in sex hormone-binding globulin, insulin, and serum lipids in postmenopausal women on a low-fat, high-fiber diet combined with exercise.
2000,
Pubmed
Tymchuk,
Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen.
1998,
Pubmed
Vandesompele,
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
2002,
Pubmed
Vergès,
Apolipoprotein A-IV levels and phenotype distribution in NIDDM.
1994,
Pubmed
Vergès,
Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects.
2001,
Pubmed
Wang,
Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL.
2011,
Pubmed
Weinberg,
Sensitivity of serum apolipoprotein A-IV levels to changes in dietary fat content.
1990,
Pubmed
Yang,
Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes.
2006,
Pubmed
Zhao,
Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values.
2011,
Pubmed
